@article{JGO5923,
author = {Harveshp Mogal and Konstantinos Chouliaras and Edward A. Levine and Perry Shen and Konstantinos I. Votanopoulos},
title = {Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes},
journal = {Journal of Gastrointestinal Oncology},
volume = {7},
number = {1},
year = {2015},
keywords = {},
abstract = {Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment option in selected patients with peritoneal dissemination from a variety of epithelial primaries. Even though a small proportion will be alive and potentially cured at 10 years, the majority will eventually develop recurrent disease. Repeat CRS/HIPEC is a valid consideration in a selected subpopulation of patients with isolated peritoneal recurrence. This review summarizes the data on patient selection, feasibility, limitations and outcomes of repeat CRS/HIPEC.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/5923}
}